Compounds > 4-pyridin-4-yl-2-sulfanylidene-5,6,7,8-tetrahydro-1H-quinoline-3-carbonitrile
Page last updated: 2024-11-09

4-pyridin-4-yl-2-sulfanylidene-5,6,7,8-tetrahydro-1H-quinoline-3-carbonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID747315
CHEMBL ID1387495
CHEBI ID120991

Synonyms (20)

Synonym
OPREA1_573924
AE-848/34089013
smr000146713
MLS000554396 ,
2-mercapto-4-pyridin-4-yl-5,6,7,8-tetrahydro-quinoline-3-carbonitrile
CHEBI:120991
4-pyridin-4-yl-2-sulfanylidene-5,6,7,8-tetrahydro-1h-quinoline-3-carbonitrile
AKOS004121755
AKOS005462111
4-(pyridin-4-yl)-2-sulfanyl-5,6,7,8-tetrahydroquinoline-3-carbonitrile
STK529023
HMS2285E06
bdbm80141
cid_747315
4-(4-pyridyl)-2-thioxo-5,6,7,8-tetrahydro-1h-quinoline-3-carbonitrile
CHEMBL1387495
Q27209226
sr-01000198669
SR-01000198669-1
109619-38-7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
bipyridinesCompounds containing a bipyridine group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency2.50590.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency2.23870.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency12.58930.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency14.12540.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency5.01190.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency4.10950.004110.890331.5287AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
hypothetical protein, conservedTrypanosoma bruceiPotency1.00000.223911.245135.4813AID624173
regulator of G-protein signaling 4Homo sapiens (human)Potency79.43280.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.23870.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency22.38720.001815.663839.8107AID894
pyruvate kinase PKM isoform aHomo sapiens (human)Potency22.38720.04017.459031.6228AID1631; AID1634
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
gemininHomo sapiens (human)Potency2.59290.004611.374133.4983AID624296
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency44.66840.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency5.62340.251215.843239.8107AID504327
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency2.39340.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)2.21000.270026.3638100.0000AID504719
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)100.00001.480014.526761.2000AID504722
Cullin-4AHomo sapiens (human)IC50 (µMol)2.68002.68002.68002.6800AID1619178
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
G1/S transition of mitotic cell cycleCullin-4AHomo sapiens (human)
in utero embryonic developmentCullin-4AHomo sapiens (human)
DNA repairCullin-4AHomo sapiens (human)
DNA damage responseCullin-4AHomo sapiens (human)
spermatogenesisCullin-4AHomo sapiens (human)
cell population proliferationCullin-4AHomo sapiens (human)
positive regulation of cell population proliferationCullin-4AHomo sapiens (human)
protein ubiquitinationCullin-4AHomo sapiens (human)
hemopoiesisCullin-4AHomo sapiens (human)
negative regulation of granulocyte differentiationCullin-4AHomo sapiens (human)
cellular response to UVCullin-4AHomo sapiens (human)
somatic stem cell population maintenanceCullin-4AHomo sapiens (human)
T cell activationCullin-4AHomo sapiens (human)
ribosome biogenesisCullin-4AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCullin-4AHomo sapiens (human)
positive regulation of protein catabolic processCullin-4AHomo sapiens (human)
rhythmic processCullin-4AHomo sapiens (human)
intrinsic apoptotic signaling pathwayCullin-4AHomo sapiens (human)
ubiquitin-dependent protein catabolic process via the C-end degron rule pathwayCullin-4AHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCullin-4AHomo sapiens (human)
regulation of DNA damage checkpointCullin-4AHomo sapiens (human)
regulation of nucleotide-excision repairCullin-4AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
protein bindingCullin-4AHomo sapiens (human)
ubiquitin protein ligase bindingCullin-4AHomo sapiens (human)
ubiquitin protein ligase activityCullin-4AHomo sapiens (human)
ubiquitin ligase complex scaffold activityCullin-4AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusCullin-4AHomo sapiens (human)
cytoplasmCullin-4AHomo sapiens (human)
nucleusCullin-4AHomo sapiens (human)
nucleoplasmCullin-4AHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexCullin-4AHomo sapiens (human)
Cul4-RING E3 ubiquitin ligase complexCullin-4AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510